Connect® MM- The Multiple Myeloma Disease Registry
Terminated
3,011 enrolled
CPIT001
Phase 1/2 Terminated
46 enrolled 13 charts
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
Phase 1 Terminated
96 enrolled
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Phase 2 Terminated
63 enrolled 11 charts
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma
Phase NA Terminated
1 enrolled
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
Terminated
50 enrolled
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
Phase 1 Terminated
35 enrolled 10 charts
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
Phase 2 Terminated
13 enrolled 9 charts
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Phase 1/2 Terminated
200 enrolled
iinnovate-3
Phase 1/2 Terminated
15 enrolled 12 charts
iinnovate-1
Phase 1/2 Terminated
272 enrolled 67 charts
iinnovate-2
Phase 1 Terminated
15 enrolled 15 charts
RE-NEZ-SENS
Phase NA Terminated
5 enrolled
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Phase 2 Terminated
146 enrolled
AlloRelapseMM
Phase 3 Terminated
28 enrolled
A Study of WVT078 in Patients With Multiple Myeloma (MM)
Phase 1 Terminated
56 enrolled
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Phase 1/2 Terminated
130 enrolled
CARTIFAN-1
Phase 2 Terminated
123 enrolled
TOMMY
Phase NA Terminated
13 enrolled 10 charts
DC15-MM-01
Phase 1 Terminated
4 enrolled
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
Phase 1 Terminated
6 enrolled
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Phase 1/2 Terminated
15 enrolled 15 charts
LIMBER
Phase 1/2 Terminated
22 enrolled 28 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
23 enrolled
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Phase 1 Terminated
37 enrolled
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
174 enrolled
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
Phase 1 Terminated
30 enrolled
AMBROBiMM
Terminated
3 enrolled
KarMMa-7
Phase 1/2 Terminated
21 enrolled
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Phase 2 Terminated
24 enrolled 8 charts
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Phase 2 Terminated
17 enrolled 9 charts
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
Phase 1 Terminated
18 enrolled
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Phase NA Terminated
2,117 enrolled 6 charts
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
1 enrolled
Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI
Phase NA Terminated
21 enrolled
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
24 enrolled
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
141 enrolled 46 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Phase 1 Terminated
55 enrolled
CART-38 in Adult AML and MM Patients
Phase 1 Terminated
11 enrolled
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase 1 Terminated
13 enrolled 10 charts
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
5 enrolled
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Phase 1/2 Terminated
32 enrolled
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
Phase 1/2 Terminated
40 enrolled
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
Phase 1 Terminated
5 enrolled
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
4 enrolled
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
20 enrolled 12 charts
FRE
Terminated
105 enrolled